

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

Claims 1-58 (canceled).

Claim 59 (previously presented). A substantially purified polypeptide comprising amino acids 58 through 404 of SEQ ID NO:4 or 6.

Claim 60 (previously presented). The polypeptide of claim 59 wherein said polypeptide comprises an amino acid sequence selected from the group consisting of:

- (a) an amino acid sequence extending from amino acid 58 through the C-terminus of SEQ ID NO:4 or 6;
- (b) an amino acid sequence extending from amino acid 58 through the C-terminus of SEQ ID NO:13; and
- (c) an amino acid sequence extending from amino acid 58 through the C-terminus of SEQ ID NO:15.

Claim 61 (previously presented). The polypeptide of claim 59 in non-glycosylated form.

Claim 62 (previously presented). The polypeptide of claim 59 further comprising a leucine zipper polypeptide.

Claim 63 (previously presented). The polypeptide of claim 59 further comprising an Fc polypeptide.

Claim 64 (previously presented). The polypeptide of claim 59 further comprising a peptide linker.

Claim 65 (previously presented). A composition comprising the polypeptide of claim 59 and a pharmaceutically acceptable carrier.

Claim 66 (previously presented). A substantially purified polypeptide comprising amino acids 74 through 365 of SEQ ID NO:10, 12, or 31.

Claim 67 (previously presented). The polypeptide of claim 66 wherein said polypeptide comprises an amino acid sequence selected from the group consisting of:

- (a) an amino acid sequence extending from amino acid 58 through the C-terminus of SEQ ID NO:10 or 12;
- (b) an amino acid sequence extending from amino acid 58 through the C-terminus of SEQ ID NO:14;
- (c) an amino acid sequence extending from amino acid 58 through the C-terminus of SEQ ID NO:16; and
- (d) an amino acid sequence extending from amino acid 58 through the C-terminus of SEQ ID NO:31.

Claim 68 (previously presented). The polypeptide of claim 66 in non-glycosylated form.

Claim 69 (previously presented). The polypeptide of claim 66 further comprising a leucine zipper polypeptide.

Claim 70 (previously presented). The polypeptide of claim 66 further comprising an Fc polypeptide.

Claim 71 (previously presented). The polypeptide of claim 66 further comprising a peptide linker.

Claim 72 (previously presented). A composition comprising the polypeptide of claim 66 and a pharmaceutically acceptable carrier.

Claim 73 (previously presented). A substantially purified polypeptide comprising an amino acid sequence selected from the group consisting of:

- (a) amino acids 58 through 342 of SEQ ID NO:4, 6, 10, 12, or 31;

- (b) amino acids 74 through 342 of SEQ ID NO:4, 6, 10, 12, or 31;
- (c) amino acids 74 through 404 of SEQ ID NO:4 or 6; and
- (d) amino acids 74 through 365 of SEQ ID NO:10, 12, or 31.

Claim 74 (previously presented). The polypeptide of claim 73 in non-glycosylated form.

Claim 75 (previously presented). The polypeptide of claim 73 further comprising a leucine zipper polypeptide.

Claim 76 (previously presented). The polypeptide of claim 73 further comprising an Fc polypeptide.

Claim 77 (previously presented). The polypeptide of claim 73 further comprising a peptide linker.

Claim 78 (previously presented). A composition comprising the polypeptide of claim 73 and a pharmaceutically acceptable carrier.

Claim 79 (previously presented). A substantially purified polypeptide comprising an amino acid sequence that inhibits endothelial cell migration and that shares at least 80% amino acid identity across the length of amino acids 58 through 404 of SEQ ID NO:4 or 6.

Claim 80 (previously presented). The polypeptide of claim 79, wherein said polypeptide comprises an amino acid sequence sharing 85%, 90%, 95%, or 99% amino acid identity across the length of amino acids 58 through 404 of SEQ ID NO:4 or 6.

Claim 81 (previously presented). The polypeptide of claim 79 in non-glycosylated form.

Claim 82 (previously presented). The polypeptide of claim 79 further comprising a leucine zipper polypeptide.

Claim 83 (previously presented). The polypeptide of claim 79 further comprising an Fc polypeptide.

Claim 84 (previously presented). The polypeptide of claim 79 further comprising a peptide linker.

Claim 85 (previously presented). A composition comprising the polypeptide of claim 79 and a pharmaceutically acceptable carrier.

Claim 86 (previously presented). A substantially purified polypeptide comprising an amino acid sequence that inhibits endothelial cell migration and that shares at least 80% amino acid identity across the length of amino acids 74 through 365 of SEQ ID NO:10, 12, or 31.

Claim 87 (previously presented). The polypeptide of claim 86, wherein said polypeptide comprises an amino acid sequence sharing 85%, 90%, 95%, or 99% amino acid identity across the length of amino acids 74 through 365 of SEQ ID NO:10, 12, or 31.

Claim 88 (previously presented). The polypeptide of claim 86 in non-glycosylated form.

Claim 89 (previously presented). The polypeptide of claim 86 further comprising a leucine zipper polypeptide.

Claim 90 (previously presented). The polypeptide of claim 86 further comprising an Fc polypeptide.

Claim 91 (previously presented). The polypeptide of claim 86 further comprising a peptide linker.

Claim 92 (previously presented). A composition comprising the polypeptide of claim 86 and a pharmaceutically acceptable carrier.

Claim 93.(previously presented). A substantially purified polypeptide comprising an amino acid sequence that inhibits endothelial cell migration and that shares at least 80% amino acid identity across the length of a contiguous amino acid sequence comprising amino acids 74 through 152, amino acids 189 through 250, and amino acids 287 through 342 of SEQ ID NO: 4, 6, 10, 12, or 31.

Claim 94 (previously presented). The polypeptide of claim 93, wherein said polypeptide comprises an amino acid sequence sharing 85%, 90%, 95%, or 99% amino acid identity across the length of a contiguous amino acid sequence comprising amino acids 74 through 152, amino acids 189 through 250, and amino acids 287 through 342 of SEQ ID NO: 4, 6, 10, 12, or 31.

Claim 95 (previously presented). The polypeptide of claim 93 in non-glycosylated form.

Claim 96 (previously presented). The polypeptide of claim 93 further comprising a leucine zipper polypeptide.

Claim 97 (previously presented). The polypeptide of claim 93 further comprising an Fc polypeptide.

Claim 98 (previously presented). The polypeptide of claim 93 further comprising a peptide linker.

Claim 99 (previously presented). A composition comprising the polypeptide of claim 93 and a pharmaceutically acceptable carrier.

Claim 100 (previously presented). An isolated polypeptide of claim 93 produced by a process comprising:

- (a) culturing a recombinant host cell comprising a polynucleotide having a nucleotide sequence encoding said polypeptide; and

- (b) isolating said polypeptide.

Claim 101 (previously presented). The polypeptide of claim 100, wherein said polypeptide is produced by a process comprising substantially purifying said polypeptide.

Claim 102 (previously presented). The polypeptide of claim 100, wherein said polypeptide is produced by a process comprising culturing a recombinant host cell comprising a polynucleotide having a nucleotide sequence encoding said polypeptide, wherein said nucleotide sequence is selected from the group consisting of nucleotides 172 to 1026 of SEQ ID NO:3, 5, 9, or 11; nucleotides 172 to 1212 of SEQ ID NO:3 or 5; and nucleotides 172 to 1098 of SEQ ID NO:9 or 11

Claim 103 (previously presented). The polypeptide of claim 100, wherein said polypeptide is produced by a process comprising culturing a recombinant host cell comprising a polynucleotide having a nucleotide sequence encoding said polypeptide, wherein said nucleotide sequence is selected from the group consisting of SEQ ID NO:1, 3, 7, 9, 11, and 30.

Claim 104 (previously presented). The polypeptide of claim 100, wherein said polypeptide is produced by a process comprising culturing a recombinant host cell comprising a polynucleotide having a nucleotide sequence encoding said polypeptide, wherein said nucleotide sequence encodes a polypeptide selected from the group consisting of SEQ ID NO:13, 14, 15, and 16.

Claim 105 (previously presented). The polypeptide of claim 100, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of:

- (a) amino acids 58 through 342 of SEQ ID NO:4, 6, 10, 12, or 31;
- (b) amino acids 58 through 404 of SEQ ID NO:4 or 6;
- (c) amino acids 74 through 342 of SEQ ID NO:4, 6, 10, 12, or 31;
- (d) amino acids 74 through 404 of SEQ ID NO:4 or 6;
- (e) amino acids 58 through 365 of SEQ ID NO:10, 12, or 31; and

(f) amino acids 74 through 365 of SEQ ID NO:10, 12, or 31.

Claim 106 (previously presented). The polypeptide of claim 100 in non-glycosylated form.

Claim 107 (previously presented). The polypeptide of claim 100 further comprising a leucine zipper polypeptide.

Claim 108 (previously presented). The polypeptide of claim 100 further comprising an Fc polypeptide.

Claim 109 (previously presented). The polypeptide of claim 100 further comprising a peptide linker.

Claim 110 (previously presented). A composition comprising the polypeptide of claim 100 and a pharmaceutically acceptable carrier.

Claim 111 (previously presented). The polypeptide of claim 100, wherein said polypeptide is produced by a process comprising culturing a recombinant host cell into which a polynucleotide comprising a nucleotide sequence encoding said polypeptide has been introduced.